Navigation Links
GEN reports on recent progress in Alzheimer's research
Date:8/7/2012

New Rochelle, NY, August 7, 2012The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN.

"Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer's," said John Sterling, Editor-in-Chief of GEN. "Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly."

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of -amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lilly, GE Healthcare Life Sciences, and Charles River Laboratories.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. GEN reports on growth of tissue engineering revenues
4. BGI reports the completed sequence of foxtail millet genome
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. Aware, Inc. Reports First Quarter 2012 Financial Results
7. From 503-million-year-old fungi to recent earthquakes: New Geology posted ahead of print
8. House funding bill will delay research progress and place new burdens on NIH
9. Guam conservation efforts progress
10. New report evaluates progress of Everglades Restoration Plan
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN reports on recent progress in Alzheimer's research
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: